Passage End Period Cash Flow vs Depreciation Analysis
PASG Stock | USD 0.78 0.02 2.63% |
Passage Bio financial indicator trend analysis is much more than just breaking down Passage Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Passage Bio is a good investment. Please check the relationship between Passage Bio End Period Cash Flow and its Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
End Period Cash Flow vs Depreciation
End Period Cash Flow vs Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Passage Bio End Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Passage Bio's End Period Cash Flow and Depreciation is -0.08. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Passage Bio, assuming nothing else is changed. The correlation between historical values of Passage Bio's End Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Passage Bio are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of End Period Cash Flow i.e., Passage Bio's End Period Cash Flow and Depreciation go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
End Period Cash Flow
Depreciation
Depreciation indicates how much of Passage Bio value has been used up. For tax purposes Passage Bio can deduct the cost of the tangible assets it purchases as business expenses. However, Passage Bio must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most indicators from Passage Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Passage Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.The current Selling General Administrative is estimated to decrease to about 34.6 M. The current Issuance Of Capital Stock is estimated to decrease to about 142.5 K
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 343K | 2.3M | 2.0M | 2.0M | Depreciation And Amortization | 1.5M | 3.7M | 3.7M | 2.8M |
Passage Bio fundamental ratios Correlations
Click cells to compare fundamentals
Passage Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Passage Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 178.6M | 328.0M | 355.1M | 243.5M | 150.5M | 236.4M | |
Other Current Liab | 3.1M | 15.9M | 20.1M | 7.7M | 8.3M | 10.1M | |
Total Current Liabilities | 3.7M | 21.2M | 29.5M | 18.4M | 16.3M | 16.4M | |
Total Stockholder Equity | 174.4M | 304.7M | 318.7M | 201.4M | 111.3M | 201.3M | |
Net Tangible Assets | (56.3M) | 304.7M | 318.7M | 201.4M | 231.6M | 166.4M | |
Property Plant And Equipment Net | 1.1M | 2.8M | 23.8M | 42.2M | 32.2M | 18.7M | |
Net Debt | (158.9M) | (135.0M) | (129.0M) | (7.5M) | 4.6M | 4.8M | |
Retained Earnings | (58.7M) | (170.9M) | (356.3M) | (492.4M) | (594.5M) | (564.7M) | |
Accounts Payable | 629K | 5.3M | 9.4M | 4.1M | 1.3M | 1.2M | |
Cash | 158.9M | 135.0M | 129.0M | 34.6M | 21.7M | 20.6M | |
Non Current Assets Total | 12.8M | 8.0M | 30.0M | 46.5M | 32.6M | 23.8M | |
Non Currrent Assets Other | 11.8M | 5.2M | 6.2M | 4.3M | 433K | 411.4K | |
Other Assets | 11.8M | 2.8M | 0.0 | 4.3M | 1.0 | 0.95 | |
Cash And Short Term Investments | 158.9M | 304.8M | 315.8M | 189.6M | 114.3M | 203.2M | |
Common Stock Shares Outstanding | 45.8M | 38.6M | 53.3M | 54.4M | 54.7M | 49.7M | |
Liabilities And Stockholders Equity | 178.6M | 328.0M | 355.1M | 243.5M | 150.5M | 236.4M | |
Non Current Liabilities Total | 580K | 2.1M | 6.9M | 23.8M | 22.9M | 13.6M | |
Other Current Assets | 6.9M | 12.4M | 9.3M | 7.4M | 3.7M | 6.4M | |
Other Stockholder Equity | 233.0M | 475.6M | 675.3M | 694.7M | 705.8M | 510.6M | |
Total Liab | 4.3M | 23.3M | 36.4M | 42.2M | 39.3M | 35.0M | |
Net Invested Capital | 174.4M | 304.7M | 318.7M | 201.4M | 111.3M | 201.3M | |
Property Plant And Equipment Gross | 1.1M | 2.8M | 23.8M | 22.5M | 39.4M | 41.4M | |
Total Current Assets | 165.8M | 317.2M | 325.1M | 197.0M | 118.0M | 212.0M | |
Net Working Capital | 162.1M | 296.0M | 295.6M | 178.7M | 101.6M | 195.6M | |
Property Plant Equipment | 1.1M | 2.8M | 23.8M | 22.5M | 25.9M | 27.2M |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.